(Total Views: 347)
Posted On: 02/26/2018 9:47:43 PM
Post# of 72436
It really is going to be interesting how this unfolds. There are just so many possibilities in how this shakes down. I will give Leo a ton more credit than most because I believe he has done an unbelievable job taking this company thru 7 successful human trials and hopefully in the next 30 days the tally will be 8! And doing that with only diluting 50 million-ish since I have been involved.
I have been feeling a difference in tone and PR style for quite some time and I feel that is because major eyes and discussions have been taking place.
50 Million shares is nothing to go from PRE-CLINICAL with really only 2 drugs (P and K) to 8 SUCCESSFUL HUMAN clinical trials and adding Brilacidin which has the potential of WHO knows how many indications it can treat!!! And 3 of those 8 trials will put those drugs into phase 3 (B-ABSSSI - P for psoriasis - B-OM)
I feel B-OM will be first to partner, however there is a gut feeling that Kevetrin may jump in front after the successful phase 2 Ovarian trial. It would be a very small deal with heavy backend and royalties but the BP industry cannot ignore what Kevetrin is doing - it;s the ORAL formulation and that UNKNOWN is what hinders a HUGE deal......like today. So does Leo feel more value can be gained if Dr. M can get it straight.....or do they want to move fast with more power and knowledge to help with the formulation? It seems like the formulation is almost confirmed so who knows.......But either way we are part of a company that is producing the first NON_TOXIC P53 altering drug.
It will be interesting if we don't hear news for the upcoming weeks leading into the DATA lock PR for P. IPIX has their hands full that is for sure!
LONG AND STRONG!
I have been feeling a difference in tone and PR style for quite some time and I feel that is because major eyes and discussions have been taking place.
50 Million shares is nothing to go from PRE-CLINICAL with really only 2 drugs (P and K) to 8 SUCCESSFUL HUMAN clinical trials and adding Brilacidin which has the potential of WHO knows how many indications it can treat!!! And 3 of those 8 trials will put those drugs into phase 3 (B-ABSSSI - P for psoriasis - B-OM)
I feel B-OM will be first to partner, however there is a gut feeling that Kevetrin may jump in front after the successful phase 2 Ovarian trial. It would be a very small deal with heavy backend and royalties but the BP industry cannot ignore what Kevetrin is doing - it;s the ORAL formulation and that UNKNOWN is what hinders a HUGE deal......like today. So does Leo feel more value can be gained if Dr. M can get it straight.....or do they want to move fast with more power and knowledge to help with the formulation? It seems like the formulation is almost confirmed so who knows.......But either way we are part of a company that is producing the first NON_TOXIC P53 altering drug.
It will be interesting if we don't hear news for the upcoming weeks leading into the DATA lock PR for P. IPIX has their hands full that is for sure!
LONG AND STRONG!
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)